This report lays the foundation for an original immunotherapy strategy for prostate cancer targeting Gal-1 not in the tumor cell, but in tumor-associated T lymphocytes, highlighting the necessity to identify which cells within the tumor environment express functionally active galectins. This evidence concerns the gene LGALS1 and prostate cancer.